Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Lee C. Zhao, MD, Gaines Blasdel, Augustus Parker, and Rachel Bluebond-Langner, MD
Tension between realistic goals and unrealistic views about how to achieve them is compounded when patients are eager to revise a prior surgeon’s gender-affirming procedure.
AMA J Ethics. 2023;25(6):E391-397. doi:
10.1001/amajethics.2023.391.
Feminism plays critical roles in innovating health care policies and practices. Feminist insights into clinicians as gatekeepers to gender-transition interventions can help resist tendencies to pathologize transgender.
AMA J Ethics. 2016;18(11):1132-1138. doi:
10.1001/journalofethics.2016.18.11.msoc1-1611.
One transgender patient draws upon his transition experiences to suggest strategies for health care professionals looking to be more responsive to transgender patients’ needs.
AMA J Ethics. 2016;18(11):1139-1146. doi:
10.1001/journalofethics.2016.18.11.mnar1-1611.